A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)

2024-518976-30-00 Protocol VIS171-103 Human pharmacology (Phase I) - Other Authorised, recruiting

Start 2 Jul 2025 · Status Authorised, recruiting · 4 EU/EEA countries · 12 sites · Protocol VIS171-103

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 30
Countries 4
Sites 12

Systemic lupus erythematosus

Key facts

Sponsor
Otsuka Pharmaceutical Development & Commercialization Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
2 Jul 2025 → ongoing
Decision date (initial)
2025-05-15
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2024-518976-30-00
ClinicalTrials.gov
NCT06799520

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Systemic lupus erythematosus

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Otsuka Pharmaceutical Development & Commercialization Inc.

Sponsor organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Address
2440 Research Boulevard
City
Rockville
Postcode
20850-3238
Country
United States

Scientific contact point

Organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Contact name
EU Clinical Trials Helpdesk

Public contact point

Organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Contact name
EU Clinical Trials Helpdesk

Locations

4 EU/EEA countries · 12 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ongoing, recruitment ended 4 2
Poland Ended 6 4
Romania Ongoing, recruitment ended 4 2
Spain Ongoing, recruitment ended 7 4
Rest of world
Moldova, Republic of, Turkey
9

Investigational sites

Bulgaria

2 sites · Ongoing, recruitment ended
Multispecialty hospital for active treatment Sveta Sofia EOOD
Department of Dermatology and Venereology, Bulevard Bilgariya 104, 1404, Sofiya
University Multiprofile Hospital For Active Treatment St. Ivan Rilski EAD
Department of Rheumatology, Ulitsa Urvich 13, 1612, Sofia

Poland

4 sites · Ended
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Centrum Wsparcia Badań Klinicznych, Ul. Szaserow 128, 04-141, Warsaw
Uniwersytecki Szpital Kliniczny W Poznaniu
Uniwersytecki Ośrodek Wczesnych Faz, Ul. Dluga 1/2, 61-848, Poznan
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
Centrum Wsparcia Badań Klinicznych, Ul. Spartanska 1, 02-637, Warsaw
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
Oddział Kliniczny Dermatologii Ogólnej i Onkologicznej, Ul. Borowska 213, 50-556, Wroclaw

Romania

2 sites · Ongoing, recruitment ended
Spitalul Clinic Judetean De Urgenta Cluj
Arensia Exploratory Medicine at Spitalul Clinic Județean de Urgență Cluj, Strada Clinicilor 3-5, 400006, Cluj-Napoca
Arensia Clinics S.R.L.
Arensia Clinics S.R.L., Intrarea Tudor Stefan 38-40, 011658, Bucharest

Spain

4 sites · Ongoing, recruitment ended
Hospital Universitari Vall D Hebron
Servicio de Nefrologia, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario La Paz
Servicio de Medicina Interna, Paseo De La Castellana 261, 28046, Madrid
Complexo Hospitalario Universitario De Santiago
Servicio de Nefrologia, Calle Choupana Da S/n, 15706, Santiago De Compostela
Hospital Universitario Virgen De Las Nieves
Servicio de Medicina Interna, Avenida De Las Fuerzas Armadas 2, 18014, Granada

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-07-21 2025-07-21 2026-03-13
Romania 2025-07-02 2025-07-02 2026-03-13
Spain 2025-11-06 2025-11-06 2026-03-13

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-01-31 Spain Acceptable
2025-05-14
2025-05-15
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-06-23 Spain Acceptable
2025-05-14
2025-06-23
3 SUBSTANTIAL MODIFICATION SM-1 2025-07-30 Spain Acceptable
2025-09-09
2025-09-09
4 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-11 Spain Acceptable
2025-09-09
2025-12-11
5 NON SUBSTANTIAL MODIFICATION NSM-3 2025-12-19 Spain Acceptable
2025-09-09
2025-12-19
6 NON SUBSTANTIAL MODIFICATION NSM-4 2026-01-08 Spain Acceptable
2025-09-09
2026-01-08
7 NON SUBSTANTIAL MODIFICATION NSM-5 2026-03-31 Spain Acceptable
2025-09-09
2026-03-31